Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails

Journal of Clinical Oncology

Volumn 23, Issue 9, 2005, Pages 1867-1874

  Sessa, Cristiana ^a   De Braud, Filippo ^a   Perotti, Antonella ^a   Bauer, Jean ^a   Curigliano, Giuseppe ^a   Noberasco, Cristina ^a   Zanaboni, Flavia ^a   Gianni, Luca ^a   Marsoni, Silvia ^a   Jimeno, José ^a   D'Incalci, Maurizio ^a   Dall'ó, Elisa ^a   Colombo, Nicoletta ^a  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; METOCLOPRAMIDE; PLATINUM; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; ISOQUINOLINE DERIVATIVE; TAXANE; TAXOID; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CARCINOMA; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; SCLEROTIC PHLEBITIS; SEPTIC THROMBOSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE; TREATMENT REFUSAL; TREATMENT RESPONSE; AFTERCARE; CLASSIFICATION; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; SALVAGE THERAPY;

ADULT; AFTERCARE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CISPLATIN; DIOXOLES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; MIDDLE AGED; OVARIAN NEOPLASMS; SALVAGE THERAPY; TAXOIDS; TETRAHYDROISOQUINOLINES; TREATMENT FAILURE;

EID: 20144377216     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.032     Document Type: Article

References (26)

1. Cannistra SA, Bast RC Jr, Berek JS, et al: Progress in the management of gynecologic cancer: Consensus summary statement. J Clin Oncol 21:129-132, 2003
2. Bookman MA: Developmental chemotherapy in advanced ovarian cancer: Incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Semin Oncol 29:20-31, 2002
3. Guan YSR, Rinehart K: Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ectenascidia turbinata. J Biomol Struct Dyn 10:793-818, 1993
4. Zewail-Foote M, Hurley LH: Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove. J Med Chem 42:2493-2497, 1999
5. Minuzzo M, Marchini S, Broggini M, et al: Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 97:6780-6784, 2000
6. Jin S, Gorfajn B, Faircloth G, et al: Ectein-ascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 97:6775-6779, 2000
7. Marchini S, Marrazzo E, Bonomi R, et al: Molecular characterization of two human cancer cell lines selected in vitro for chemotherapeutic drug resistance to ET-743. Eur J Cancer 41:323-333, 2005
8. Erba E, Bergamaschi D, Bassano L, et al: Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37:97-105, 2001
9. Damia G, Silvestri S, Carrassa L, et al: Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92:583-588, 2001
10. Takebayashi Y, Pourquier P, Zimonjic DB, et al: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7:961-966, 2001
11. Valoti G, Nicoletti Ml, Pellegrino A, et al: Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4:1977-1983, 1998
12. Twelves C, Hoekman K, Bowman A, et al: Phase I and pharmacokinetic study of Yondelis (ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 39:1842-1851, 2003
13. Taamma A, Misset JL, Riofrio M, et al: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19:1256-1265, 2001
14. Forouzesh BHM, Denis L, Schwartz G, et al: Phase I and pharmacokinetic study of ET-743 (Yondelis), a minor groove DNA binder, administered weekly to patients with advanced cancer. Eur J Cancer 37:32, 2001
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Gehan E: The determination of the number of patients required in a preliminary and follow up trial of a new chemotherapeutic agent. J Chron Dis 13:346-353, 1961
17. Yovine A, Riofrio M, Blay JY, et ai: Phase II study of ecteinascidin-743 in advanced pre-treated soft tissue sarcoma patients. J Clin Oncol 22:890-899, 2004
18. Donald S, Verschoyle RD, Greaves P, et al: Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res 63:5902-5908, 2003
19. Grasselli G, Colombo N, Perez C, et al: Dose-finding and pharmacokinetic (PK) study of ecteinascidin-743 (ET, Yondelis) and cisplatin (P) combination in pre-treated patients with selected advanced solid tumors. Proc Am Soc Clin Oncol 21:542, 2003 (abstr 542)
20. Krasner CNM, Chan S, Braly S, et al: A phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma. Proc Am Soc Clin Oncol 22:458, 2004 (abstr 5045)
21. Samuels BR, Chawla D, Schuetze SP, et al: Randomised phase II study of trabectedin (ET-743) given by two different dosing schedules in patients with leiomyosarcomas or liposarcomas refractory to conventional doxorubicin and ifosfamide chemotherapy. Proc Am Soc Clin Oncol 22:814, 2004 (abstr 9000)
22. Gordon AN, Granai CO, Rose PG, et al: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18:3093-3100, 2000
23. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322, 2001
24. Bookman MA, Malmstrom H, Bolis G, et al: Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345-3352, 1998
25. McGuire WP, Blessing JA, Bookman MA, et al: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 18:1062-1067, 2000
26. Friedlander M, Millward MJ, Bell D, et al.: A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9:1343-1345, 1998